Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway-Reference-Cited by-同舟云学术

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

Author:

Hamnvik Ole-Petter R.¹,Choueiri Toni K.²,Turchin Alexander¹,McKay Rana R.²,Goyal Lipika³,Davis Michael¹,Kaymakcalan Marina D.⁴,Williams Jonathan S.¹

Affiliation:

1. Brigham and Women's Hospital; Division of Endocrinology, Diabetes and Hypertension; Boston Massachusetts

2. Dana-Farber Cancer Institute; Boston Massachusetts

3. Massachusetts General Hospital Cancer Center; Boston Massachusetts

4. Dana Farber Cancer Institute; Pharmacy Boston Massachusetts

Funder

National Center for Advancing Translational Sciences

Trust Family and Michael Brigham funds for Kidney Cancer Research

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Anti-VEGF therapies in the clinic;Meadows;Cold Spring Harb Perspect Med.,2012

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献